The Federal Trade Commission (FTC) was correct in its application of a recent Supreme Court decision and its finding that payments between a generic and brand name drugmaker amounted to a pay-for-delay agreement, 82 professors of law, economics, business and medicine write in an amici curiae brief to the US Court of Appeals for the 5th Circuit.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,